Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. insider plans to sell common stock under Rule 144. A person associated with Zoetis filed a notice to sell 3,662 shares of Zoetis common stock through Merrill Lynch on or about 02/13/2026 on the NYSE, with an aggregate market value of $472,727.58.
The filing shows these shares were accumulated mainly through vesting of restricted stock unit and performance share awards, plus an employee stock option exercise between 2022 and 2025. Zoetis had 422,127,709 common shares outstanding when the notice was prepared.
Zoetis Inc. is a global animal health company focused on medicines, vaccines, diagnostics and biodevices for companion animals and livestock. It operates in two segments: U.S. revenue was $5,097 million and International revenue was $4,254 million in 2025.
Companion animal products generated about 70% of 2025 revenue, livestock about 29%, with contract manufacturing and human health diagnostics around 1%. Flagship lines Simparica/Simparica Trio and Apoquel/Apoquel Chewable contributed roughly 16% and 12% of revenue; the top ten product lines made up about 57%.
Zoetis invested $698 million in R&D in 2025 across more than 300 programs and employed about 14,500 people worldwide. The company maintains a 21-site manufacturing network, extensive use of contract manufacturers, and operates under complex global regulatory, environmental, data privacy and AI-related frameworks.
Zoetis Inc. reported modest growth for the fourth quarter and full year 2025 and issued guidance for 2026. Fourth quarter revenue was $2.4 billion, up 3% year over year, with net income of $603 million, or $1.37 per diluted share. Adjusted net income was $648 million, or $1.48 per diluted share.
For full year 2025, revenue reached $9.5 billion, up 2%, while net income rose to $2.7 billion, or $6.02 per diluted share. Adjusted net income was $2.8 billion, or $6.41 per diluted share, reflecting 6% growth. International revenue benefited from timing changes related to an expected fiscal year alignment, adding about 2.5% to 3.5% to fourth quarter International sales.
The company highlighted approvals for its long-acting osteoarthritis pain monoclonal antibodies Lenivia and Portela in Canada and the EU, and the acquisition of Veterinary Pathology Group in the UK and Ireland. For 2026, Zoetis guided to revenue of $9.825 billion to $10.025 billion and adjusted diluted EPS of $7.00 to $7.10, implying 3% to 5% organic operational revenue growth.
Zoetis Inc. executive Kevin Esch reported routine equity compensation activity. On February 6 and 8, 2026, he acquired 43 and 50 shares of Zoetis common stock, respectively, through the vesting and settlement of restricted stock units.
On those same dates, he disposed of 15 and 18 shares of common stock at $127.42 per share. Following these transactions, he directly held 327 shares of Zoetis common stock and indirectly held 122.9323 common stock equivalents in the Zoetis Savings Plan, a 401(k) plan, as of December 31, 2025. He also reported outstanding restricted stock units covering 44, 307.4298 and 775.5724 shares of common stock, subject to multi‑year vesting schedules tied to continued service.
Zoetis Inc. executive Ashton Nicholas reported routine equity activity tied to restricted stock units (RSUs). On February 6, 2026, 381 shares of common stock were acquired upon RSU vesting, with 200 shares withheld at $127.42 per share for taxes, leaving 1,275 shares directly owned. On February 8, 2026, 398 shares were acquired from additional RSU vesting, with 209 shares withheld at $127.42, resulting in 1,464 common shares held directly after these transactions. Nicholas also holds 2,250.4257 RSUs, each representing a contingent right to receive one Zoetis common share as they vest over multi‑year schedules.
Zoetis Inc. Executive Vice President Roxanne Lagano reported routine equity compensation activity involving restricted stock units and common shares. On February 6, 2026, 544 shares of common stock were acquired upon RSU vesting, and 217 shares were withheld at a price of $127.42 for tax obligations. On February 8, 2026, a further 605 shares were acquired upon RSU vesting, with 221 shares withheld at $127.42 for taxes.
Following these transactions, Lagano directly owned 15,140 shares of Zoetis common stock and held 833.684 common stock equivalents indirectly through the Zoetis Savings Plan, a 401(k) plan, as of December 31, 2025. She also held 2,250.4257 RSUs that vest in installments on the first, second, and third anniversaries of the respective grant dates, subject to continued service and certain earlier-vesting events.
Zoetis Inc. Chief Financial Officer Joseph Wetteny reported equity award activity and tax-related share withholding. On February 6, 2026, 1,388 restricted stock units vested and were settled into common shares, with 515 shares withheld at $127.42 per share for taxes. On February 8, 2026, another 1,409 units vested into common shares, with 483 shares withheld at $127.42 per share for taxes. After these transactions, Wetteny directly owned 20,766 shares of Zoetis common stock and held 6,152.6517 RSUs that remain outstanding.
Zoetis Inc. Executive Vice President Ferran Astorga Jeannette reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 6 and 8, 2026, RSUs vested and were settled into 206 and 218 shares of Zoetis common stock, respectively, with no cash exercise price.
To cover withholding obligations, the company withheld 92 and 97 shares of common stock at a price of $127.42 per share. After these transactions, the executive directly held 1,443 shares of Zoetis common stock and 1,294.6543 RSUs, which each represent a contingent right to receive one share of common stock as they vest over future anniversaries of the original grant dates.
Zoetis Inc. Executive Vice President Jamie Brannan reported routine equity compensation activity. On February 6 and 8, 2026, restricted stock units (RSUs) vested and were settled in Zoetis common stock, resulting in acquisitions of 529 and 380 shares, respectively.
To cover tax withholding on these vestings, 249 shares on February 6 and 179 shares on February 8 were withheld at a price of $127.42 per share. After these transactions, Brannan directly owned 2,652 shares of Zoetis common stock and held 445 common stock equivalents indirectly through the UK Share Ownership Plan.
The filing also shows 3,614.0741 RSUs outstanding under the Zoetis Amended and Restated 2013 Equity and Incentive Plan and related dividend equivalents, which represent contingent rights to receive the same number of Zoetis common shares upon future vesting.
Zoetis Inc. Executive Vice President Rimma Driscoll reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 6, 2026, 222 shares of common stock were acquired upon RSU vesting, and 89 shares were withheld at a price of $127.42 per share to cover taxes, leaving 5,325 shares of common stock directly owned. On February 8, 2026, a further 192 shares were acquired upon RSU vesting, with 77 shares withheld at $127.42 per share for taxes, resulting in 5,440 directly owned shares. The derivative table shows related RSU positions, including ongoing RSU awards that vest in thirds on the first, second, and third anniversaries of the original grant dates.